Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Short Interest Update

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) was the recipient of a large decline in short interest in February. As of February 27th, there was short interest totaling 4,572,652 shares, a decline of 12.8% from the February 12th total of 5,244,475 shares. Approximately 3.5% of the company’s stock are short sold. Based on an average trading volume of 1,025,083 shares, the days-to-cover ratio is currently 4.5 days. Based on an average trading volume of 1,025,083 shares, the days-to-cover ratio is currently 4.5 days. Approximately 3.5% of the company’s stock are short sold.

Insider Activity

In other Alnylam Pharmaceuticals news, EVP Pushkal Garg sold 2,242 shares of Alnylam Pharmaceuticals stock in a transaction on Friday, February 13th. The shares were sold at an average price of $310.08, for a total value of $695,199.36. Following the transaction, the executive vice president directly owned 24,848 shares of the company’s stock, valued at approximately $7,704,867.84. The trade was a 8.28% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Jeffrey V. Poulton sold 2,780 shares of the company’s stock in a transaction on Monday, January 12th. The stock was sold at an average price of $362.87, for a total value of $1,008,778.60. Following the transaction, the executive vice president directly owned 57,465 shares in the company, valued at approximately $20,852,324.55. The trade was a 4.61% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 53,923 shares of company stock worth $18,072,087. Insiders own 1.20% of the company’s stock.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

A number of large investors have recently made changes to their positions in ALNY. Vanguard Group Inc. grew its position in Alnylam Pharmaceuticals by 2.0% during the third quarter. Vanguard Group Inc. now owns 13,565,452 shares of the biopharmaceutical company’s stock worth $6,185,846,000 after buying an additional 268,313 shares during the period. Capital Research Global Investors lifted its position in shares of Alnylam Pharmaceuticals by 0.4% during the 3rd quarter. Capital Research Global Investors now owns 7,222,840 shares of the biopharmaceutical company’s stock valued at $3,293,516,000 after acquiring an additional 31,184 shares during the period. Groupama Asset Managment lifted its position in shares of Alnylam Pharmaceuticals by 160.4% during the 3rd quarter. Groupama Asset Managment now owns 4,032,082 shares of the biopharmaceutical company’s stock valued at $18,610,000 after acquiring an additional 2,483,697 shares during the period. Geode Capital Management LLC boosted its stake in shares of Alnylam Pharmaceuticals by 6.1% during the 4th quarter. Geode Capital Management LLC now owns 2,650,722 shares of the biopharmaceutical company’s stock worth $1,056,884,000 after acquiring an additional 151,480 shares in the last quarter. Finally, Norges Bank purchased a new stake in shares of Alnylam Pharmaceuticals during the 4th quarter worth approximately $895,816,000. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Stock Up 0.5%

ALNY opened at $320.42 on Wednesday. The company has a debt-to-equity ratio of 1.28, a current ratio of 2.76 and a quick ratio of 2.71. Alnylam Pharmaceuticals has a 12 month low of $205.87 and a 12 month high of $495.55. The stock has a market capitalization of $42.49 billion, a P/E ratio of 187.38 and a beta of 0.36. The business has a 50 day simple moving average of $341.06 and a 200-day simple moving average of $407.61.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings data on Thursday, February 12th. The biopharmaceutical company reported $1.25 earnings per share for the quarter, missing analysts’ consensus estimates of $1.43 by ($0.18). Alnylam Pharmaceuticals had a return on equity of 69.02% and a net margin of 6.43%.The business had revenue of $1.10 billion for the quarter, compared to analyst estimates of $1.16 billion. During the same period in the prior year, the company earned ($0.65) EPS. The company’s revenue was up 84.9% on a year-over-year basis. On average, equities analysts anticipate that Alnylam Pharmaceuticals will post -1.7 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on the company. Wall Street Zen downgraded Alnylam Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Saturday, February 14th. Weiss Ratings raised Alnylam Pharmaceuticals from a “sell (d-)” rating to a “hold (c-)” rating in a report on Thursday, January 15th. Wells Fargo & Company dropped their price target on Alnylam Pharmaceuticals from $479.00 to $376.00 and set an “equal weight” rating on the stock in a research note on Tuesday, January 20th. Bank of America restated a “buy” rating on shares of Alnylam Pharmaceuticals in a report on Thursday, February 12th. Finally, Leerink Partners decreased their price objective on shares of Alnylam Pharmaceuticals from $370.00 to $351.00 and set a “market perform” rating for the company in a research report on Monday, December 15th. One investment analyst has rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and six have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $468.84.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.